Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? (Q37967115)

26 August 2017

title

Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? (English)

1 reference

26 August 2017

0 references

George J Netto

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

13 December 2011

1 reference

26 August 2017

published in

Nature Reviews Urology

1 reference

26 August 2017

volume

9

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

41-51

1 reference

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Molecular screening for bladder cancer: progress and potential.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Molecular pathogenesis and diagnostics of bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Urothelial tumorigenesis: a tale of divergent pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Prognostic significance of p27Kip1expression in bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Applications of array technology: identification of molecular targets in bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Expression of the epidermal growth factor receptor family in normal and malignant urothelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Expression of E-Cadherin and α-,β-,γ-Catenins in Patients With Bladder Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

New molecular targets and novel agents in the treatment of advanced urothelial cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

The origins of urothelial carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

HER2/neu expression in bladder cancer: relationship to cell cycle kinetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Transitional research in bladder cancer: From molecular pathogenesis to useful tissue biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

p53 expression in patients with advanced urothelial cancer of the urinary bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Cyclin D3 expression in primary Ta/T1 bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Overexpression of p27kip1 in urinary bladder urothelial carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Multiplexed methylation profiles of tumor suppressor genes in bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Promoter hypermethylation identifies progression risk in bladder cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Bladder cancer: translating molecular genetic insights into clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Generation of a concise gene panel for outcome prediction in urinary bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Molecular alterations associated with bladder cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Correlation of grade of urothelial cell carcinomas and DNA histogram features assessed by flow cytometry and automated image cytometry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

[Flow cytometric DNA analysis and cytology in diagnosis and prognosis of bladder tumors: preliminary results of a comparative study of bladder lavage]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Combination of cytologic evaluation and quantitative digital cytometry is reliable in detecting recurrent disease in patients with urinary diversions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

S-phase fraction in superficial urothelial carcinoma of the bladder--a prospective, long-term, follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Promoter analysis of epigenetically controlled genes in bladder cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

A MicroRNA expression profile defining the invasive bladder tumor phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Distinct microRNA alterations characterize high- and low-grade bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Novel strategies for treating relapsed/refractory urothelial carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Targeted therapy of urological tumours. Experimental field or established therapeutic approach?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Targeted therapies in bladder cancer--an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Targeting RAS signalling pathways in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Targeted therapy for locally advanced and/or metastatic bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Targeting angiogenesis in bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Multivariate analysis of the prognostic factors of primary superficial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Contemporary management of stage T1 transitional cell carcinoma of the bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Challenges of cancer biomarker profiling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.193

Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer

31 March 2020

1 reference

12 December 2020

Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer

1 reference

12 December 2020

Expression of HIF-1alpha and Glut-1 in human bladder cancer.

1 reference

12 December 2020

Prognostic value of morphometry in low grade papillary urothelial bladder neoplasms.

1 reference

12 December 2020

Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder

1 reference

12 December 2020

Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients

1 reference

12 December 2020

Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice

1 reference

12 December 2020

Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers

1 reference

12 December 2020

Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center.

1 reference

12 December 2020

Reflex UroVysion testing in suspicious urine cytology cases

1 reference

12 December 2020

UroVysion, Urine Cytology, and the College of American Pathologists: Where Should We Go From Here?

1 reference

12 December 2020

A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102.

1 reference

12 December 2020

Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors

1 reference

12 December 2020

The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.

1 reference

12 December 2020

Expression of E-Cadherin and α-, β-, γ-Catenins in Patients With Bladder Cancer

1 reference

12 December 2020

Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes

1 reference

12 December 2020

Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer

1 reference

12 December 2020

Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma

1 reference

12 December 2020

Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences

1 reference

12 December 2020

Analyses of p53 gene mutations in primary human bladder cancer

1 reference

12 December 2020

DNA ploidy of bladder cancer using bladder biopsy supernate specimens

1 reference

12 December 2020

BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers

1 reference

12 December 2020

Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2011.193

1 reference

Dimensions Publication ID

26 August 2017

1016884328

0 references

1 reference